Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation - Adeboyeje, G; Sylwestrzak, G; Barron, J J (J Manag Care Spec Pharm, 2017)
, et al.